Real-world analysis of the rationality of the clinical use of sintilimab in 279 patients

Published: 24 June 2024| Version 1 | DOI: 10.17632/jvndm5w2rc.1
Yunling Zhang, Rong Chao


Objective: Sintilimab, a recent addition to Chinese national medical insurance coverage, remains underutilized in real-world settings. This study aimed to assess the clinical use of sintilimab in real-world settings. Method: A real-world study was conducted in patients who received sintilimab at the Pharmacy Department of Anhui Chest Hospital between November 2020 and June 2023. Result: In total, 279 patients were included, comprising 240 males (86.02%). The median age was 65.38 years. Lung cancer was the most common cancer type (n=253, 90.68%). Among these patients, sintilimab was used off-label in 17 cases (6.09%). Among the 17 cases, seven patients with small cell lung cancer, bladder malignant tumor, cervical cancer, and malignant melanoma achieved stable disease, and two patients with fibrosarcoma and cervical cancer achieved a partial response. Treatment-related adverse reactions were observed in six patients (35.29%), including three thyroid dysfunction (17.65%), one rash (5.89%), one diarrhea and enteritis (5.89%), and one gastric discomfort (5.89%). Conclusion: The real-world use of sintilimab involves off-label use, which may achieve good therapeutic effects in malignant bladder tumors, colorectal cancer, and malignant melanoma.



Anhui Chest Hospital


Pharmacology, Oncology